{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "betamethasone dipropionate",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "Apply a thin film of betamethasone dipropionate ointment USP (augmented) to the affected skin areas once or twice daily. Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Betamethasone dipropionate ointment USP (augmented) is a super-high-potency topical corticosteroid.",
        "source": "US FDA label for betamethasone dipropionate (Betamethasone dipropionate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Use of betamethasone dipropionate ointment (augmented) in pediatric patients younger than 13 years of age is not recommended due to the potential for HPA axis suppression [see WARNINGS AND PRECAUTIONS ( 5.1 )] . In an open-label HPA axis safety trial in subjects 3 months to 12 years of age with atopic dermatitis, DIPROLENE AF ® Cream 0.05% was applied twice daily for 2 to 3 weeks over a mean body surface area of 58% (range 35% to 95%).",
        "source": "US FDA label for betamethasone dipropionate (Betamethasone dipropionate), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "No kidney-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for betamethasone dipropionate (Betamethasone dipropionate), retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": false
      }
    ],
    "hepatic": [
      {
        "text": "Risk factor(s) include the use of high-potency topical corticosteroids, use over a large surface area or to areas under occlusion, prolonged use, altered skin barrier, liver failure, and use in pediatric patients.",
        "source": "US FDA label for betamethasone dipropionate (Betamethasone dipropionate), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": true
      },
      {
        "text": "Factors that predispose to HPA axis suppression include the use of high-potency steroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age.",
        "source": "US FDA label for betamethasone dipropionate (Betamethasone dipropionate), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": true
      }
    ],
    "pregnancy": [
      {
        "text": "Risk Summary There are no available data on betamethasone dipropionate ointment (augmented) use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.",
        "source": "US FDA label for betamethasone dipropionate (Betamethasone dipropionate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": true
      },
      {
        "text": "Observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy.",
        "source": "US FDA label for betamethasone dipropionate (Betamethasone dipropionate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": true
      },
      {
        "text": "Advise pregnant women that betamethasone dipropionate ointment (augmented) may increase the risk of having a low birthweight infant and to use betamethasone dipropionate ointment (augmented) on the smallest area of skin and for the shortest duration possible.",
        "source": "US FDA label for betamethasone dipropionate (Betamethasone dipropionate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Risk Summary There are no data regarding the presence of betamethasone dipropionate in human milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate ointment (augmented) to women who are breastfeeding.",
        "source": "US FDA label for betamethasone dipropionate (Betamethasone dipropionate), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": true
      },
      {
        "text": "It is possible that topical administration of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk.",
        "source": "US FDA label for betamethasone dipropionate (Betamethasone dipropionate), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": true
      },
      {
        "text": "The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for betamethasone dipropionate ointment (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate ointment (augmented) or from the underlying maternal condition.",
        "source": "US FDA label for betamethasone dipropionate (Betamethasone dipropionate), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/betamethasone-dipropionate.json",
        "verbatim": true
      }
    ]
  }
}